medigraphic.com
ISSN 2078-7170 (Electronic)

2011, Number 2

<< Back Next >>

CorSalud 2011; 3 (2)

Leukocyte count and glycemia in the prognosis of patients with acute coronary syndrome. Usefulness of leuko-glycemic index

León AE, Pérez FGA

Language: Spanish
References: 39
Page: 93-102
PDF size: 203.20 Kb.


ABSTRACT

The white blood cell count and glucose levels, performed on admission in patients with acute coronary syndrome, have been demonstrated as useful tools and provide prognostic information routine hospital and medium term. In numerous studies, with a large number of individuals, has found that those with elevated glucose values, regardless of whether or not diabetics have higher in-hospital complications and more likely to die. Moreover, high levels of leukocytes have been associated with increased infarct extension, higher systolic dysfunction and hence increased complications and mortality. Recently, the index has been proposed as a useful marker leucoglucémico that easily combines both responses, although further studies are needed to validate their use in clinical practice. In this article we discuss the value of that index.


REFERENCES

  1. Fox KA, Langrish JP. Estratificación del riesgo en los síndromes coronarios agudos. Rev Esp Cardiol. 2010;63(6):629-32.

  2. Sanz A. G. Estratificación del riesgo en los sín-dromes coronarios agudos: un problema no resuel-to. Rev Esp Cardiol. 2007;60(Supl 3):23-30.

  3. Núñez J, Fácila L, Llàcer A, Sanchís J, Bodí V, Bertomeu V, et al. Valor pronóstico del recuento leucocitario en el infarto agudo de miocardio: mortalidad a largo plazo. Rev Esp Cardiol. 2005; 58(6):631-9.

  4. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: Implications for risk assessment. J Am Coll Cardiol. 2004;44(10):1945-56.

  5. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, et al. Hyperglycemia and acute coronary syndrome. A scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008;117 (12):1610-9.

  6. Zamora A, Marrugat J. Pronóstico de los pacientes diabéticos con cardiopatía isquémica. Rev Esp Cardiol. 2002;55(7):751-62.

  7. Quiroga W, Conci E, Zelaya F, Isa M, Pacheco G, Sala J, et al. Estratificación del riesgo en el infarto agudo de miocardio según el índice leucoglucé-mico. ¿El "Killip-Kimball" de laboratorio? Rev Fed Arg Cardiol. 2010;39(1):29-34.

  8. Pesaro AE, Nicolau JC, Serrano CV, Truffa R, Gaz MV, Karbstein R, et al. Influence of leukocytes and glycemia on the prognosis of patients with acute myocardial infarction. Arq Bras Cardiol. 2009;92(2): 84-8.

  9. Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol. 2005;45(10):1638-43.

  10. Undas A, Wiek I, Stêpien E, Zmudka K, Tracz W. Hyperglycemia is associated with enhanced throm-9. bin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care. 2008;31(8):1590-5.

  11. Van-de-Werf F, Bax J, Betriu A, Blomstrom-Lund-qvist C, Crea F, Falk V, et al. Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST. Rev Esp Cardiol. 2009;62(3):e1-e47.

  12. Bohórquez R, Rivera AA, Beltrán JR. Diagnóstico y tratamiento del infarto agudo del miocardio con supradesnivel del ST. En: Charria DJ, Guerra PA, Manzur F, Llamas A, Rodríguez NI, Sandoval NF, et al. Texto de Cardiología. 2da ed. Bogotá: Sociedad Colombiana de Cardiología y Cirugía Cardiovascular; 2007. p. 452-81.

  13. Kern MJ. Flujo sanguíneo coronario e isquemia coronaria. En: Libby P, Bonow RO, Mann DL, Zipes DP. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. Madrid: Elsevier; 2006. p. 1103-27.

  14. Rodríguez-Granillo GA, García-García HM, Valgi-migli M, Vaina S, Van-Mieghem C, Van-Geuns RJ, et al. Global characterization of coronary plaque rupture phenotype using three-vessel intravascular ultrasound radiofrequency data analysis. Eur Heart J. 2006;27(16):1921-7.

  15. Martín-Ventura JL, Blanco-Colio LM, Tuñón J, Muñoz-García B, Madrigal-Matute J, Moreno JA, et al. Biomarcadores en la medicina cardiovascular. Rev Esp Cardiol. 2009;62(6):677-88.

  16. García-Moll X. Marcadores de inflamación y de antiinflamación en el síndrome coronario agudo: ¿listos para usarlos en la práctica clínica? Rev Esp Cardiol. 2005;58(6):615-7.

  17. Barron HV, Harr SD, Radford MJ, Wang Y, Krumholz HM. The association between white blood cell count and acute myocardial infarction mortality in patients ≥ 65 years of age: Findings from the Cooperative Cardiovascular Project. J Am Coll Cardiol. 2001;38(6):1654-61.

  18. Núñez J, Núñez E, Bertomeu V, Fácila L, Sanchis J, Bodí V, et al. Prognostic value of baseline white blood cell count in patients with acute myocardial infarction and ST segment elevation. Heart. 2005;91(8):1094-5.

  19. Kruk M, Karcz M, Przyłuski J, Bekta P, Kepka C, Kalińczuk Ł, et al. White blood cell count adds prognostic information to the thrombolysis in myo-cardial infarction risk index in patients following primary percutaneous coronary intervention (ANIN Myocardial Infarction Registry). Int J Cardiol. 2007; 116(3):376-82.

  20. Smit J, Ottervanger J, Slingerland R, Suryapranata H, Hoorntje J, Dambrink J, et al. Successful reperfusion for acute ST elevation myocardial infarction is associated with a decrease in WBC count. J Lab Clin Med. 2006;147(6):321-6.

  21. Bodí V, Sanchis J, Núñez J, Rumiz E, Mainar L, López-Lereu P. M, et al. Linfopenia post-reperfu-sión y obstrucción microvascular en el infarto agudo de miocardio con elevación del segmento ST. Rev Esp Cardiol. 2009;62(10):1109-17.

  22. O’Donoghue M, Morrow DA, Cannon CP, Guo W, Murphy SA, Gibson CM, et al. Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrino-lytic therapy. Eur Heart J. 2008;29(8):984-91.

  23. Arruda-Olson AM, Reeder GS, Bell MR, Weston SA, Roger VL. Neutrophilia predicts death and heart failure after myocardial infarction. Circ Car-diovasc Qual Outcomes. 2009;2(6):656-62.

  24. Menon V, Lessard D, Yarzebski J, Furman M, Gore J, Goldberg R. Leukocytosis and adverse hospital outcomes after acute myocardial infarction. Am J Cardiol. 2003;92(4):368-72.

  25. Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: Is it time to inter-vene? Arterioscler Thromb Vasc Biol. 2005;25(4): 658-70.

  26. Garadah TS, Kassab S, Al-Shboul QM, Alawadi A. The threshold of admission glycemia as a predictor of adverse events in diabetic and non-diabetic patients with acute coronary syndrome. Clin Med Cardiol. 2009;3:29-36.

  27. Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Del Pinto M, Repaci S, et al. New-onset hyperglycemia and acute coronary syndrome: a systematic overview and meta-analysis. Curr Dia-betes Rev. 2010;6(2):102-10.

  28. Monteiro S, Monteiro P, Gonçalves F, Freitas M, Providência L. Hyperglycaemia at admission in acute coronary syndrome patients: prognostic value in diabetics and non-diabetics. Eur J Cardio-vasc Prev Rehabil. 2010;17(2):155-9.

  29. Vergés B, Zeller M, Dentan G, Beer J-C, Laurent Y, Janin-Manificat L, et al. Impact of fasting glycemia on short-term prognosis after acute myocardial infarction. J Clin Endocrinol Metab. 2007;92(6): 2136-40.

  30. Rocha S, Nabais S, Magalhães S, Salgado A, Azevedo P, Marques J, et al. Admission glycemia: a predictor of death after acute coronary syndrome in nondiabetic patients? Rev Port Cardiol. 2007; 26(12):1367-77.

  31. Vivas D, García-Rubira JC, González-Ferrer JJ, Núñez-Gil I, Prado N, Fernández-Ortiz A, et al. Valor pronóstico de la primera glucemia en ayunas en comparación con la glucemia al ingreso en pacientes con síndrome coronario agudo. Rev Esp Cardiol. 2008;61(5):458-64.

  32. Zarich S, Nesto R. Implications and treatment of acute hyperglycemia in the setting of acute myocardial infarction. Circulation. 2007;115(18): e436-9.

  33. Monteiro S, Gonçalves F, Monteiro P, Freitas M, Providência LA. Magnitud de la variación de la glucemia: ¿un nuevo instrumento para la evaluación del riesgo en el síndrome coronario agudo? Rev Esp Cardiol. 2009;62(10):1099-108.

  34. Palma JL. La diabetes mellitus entendida como una enfermedad cardiovascular de origen metabó-lico. Rev Esp Cardiol. 2007; 7(Supl G):H12-9.

  35. Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD, et al. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J. 2006; 27(11):1289-97.

  36. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Hata T, et al. Is admission hypergly-caemia in non-diabetic patients with acute myocar-dial infarction a surrogate for previously undiag-nosed abnormal glucose tolerance? Eur Heart J. 2006;27:2413-9.

  37. Ray KK, Cannon CP, Morrow DA, Kirtane AJ, Buros J, Rifai N, et al. Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18. Eur Heart J. 2007; 28(7):806-13.

  38. Trøseid M, Seljeflot I, Hjerkinn EM, Arnesen H. Interleukin-18 is a strong predictor of cardiovas-cular events in elderly men with the metabolic syndrome synergistic effect of inflammation and hyperglycemia. Diabetes Care. 2009;32(3):486-92.

  39. Schillinger M, Exner M, Amighi J, Mlekusch W, Sabeti S, Rumpold H, et al. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation. 2003; 108(19):2323-8.




2020     |     www.medigraphic.com